-
1.发明公开METHODS FOR PREVENTING TOXIC DRUG-DRUG INTERACTIONS IN COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS 审中-公开一种预防药物之间有毒的物质的相互作用在联合治疗与抗ErbB3基金
公开(公告)号：EP2704746A2
公开(公告)日：2014-03-12
申请号：EP12782207.0
申请日：2012-05-04
IPC分类号： A61K39/395 , A61K38/16 , A61K38/17 , A61P35/00
CPC分类号： C07K16/32 , A61K31/517 , A61K31/5377 , A61K38/005 , A61K38/16 , A61K38/17 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/90 , A61K2300/00
摘要： Methods are disclosed for preventing toxic drug-drug interactions during combination cancer therapy with a drug that is an anti-ErbB3 agent, such as an anti-ErbB3 antibody, together with a drug that is a tyrosine kinase inhibitor and/or a drug that binds to alpha- 1 acid glycoprotein (e.g., erlotinib). Health care practitioners obtaining any one of the drugs are warned that when co-administering the drug that is an anti-ErbB3 agent with either or both of a drug that is a tyrosine kinase inhibitor and a drug that binds to alpha- 1 acid glycoprotein, at least one of the co-administered drugs should be administered using a reduced dosage to prevent toxicity. In a reduced dosage, the amount of drug administered per unit time is reduced as compared to a dose that would be administered if the drug was administered as monotherapy. The reduced dosage can be, for example, a reduced drug dose or a reduced drug dosing frequency, or both. Compositions useful in practicing the disclosed methods are also provided.
-
2.发明公开USE OF INHIBITORS OF EGFR-FAMILY RECEPTORS IN THE TREATMENT OF HORMONE REFRACTORY BREAST CANCERS 审中-公开表皮生长因子受体受体家族抑制剂的激素难治的乳腺癌治疗中的应用
公开(公告)号：EP2683741A2
公开(公告)日：2014-01-15
申请号：EP12711080.7
申请日：2012-03-12
IPC分类号： C07K16/32 , A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/4196 , A61K31/5685 , A61K45/06 , A61K2039/505 , C07K16/32 , C07K16/468 , A61K2300/00
摘要： Provided are methods of suppressing growth of hormone refractory breast tumors by contacting tumor cells with an ErbB3 inhibitor, preferably an anti-ErbB3 antibody. Also provided are methods for treating hormone refractory breast cancer in a patient by administering to the patient an inhibitor of heregulin binding to ErbB3 or to ErbB2/ErbB3 heterodimer, which inhibitor is an anti-ErbB3 antibody or an anti-ErbB2 antibody. The treatment methods can further comprise selecting a patient having a hormone refractory breast cancer and then administering the inhibitor to the patient. The treatment methods may also comprise administering an estrogen receptor antagonist, or an aromatase inhibitor to the patent and may at further comprise administering to the patient at least one additional anti-cancer agent that is not an ErbB3 inhibitor, an estrogen receptor antagonist, or an aromatase inhibitor to the patient in combination with the ErbB3 inhibitor.
-
3.发明公开COMBINATION THERAPY FOR TREATING HER2-POSITIVE CANCERS 审中-公开KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON HER2-POSITIVEN KARZINOMEN
公开(公告)号：EP2925361A1
公开(公告)日：2015-10-07
申请号：EP13860427.7
申请日：2013-12-03
发明人： MOYO, Victor , HENDRIKS, Bart S. , WICKHAM, Thomas , GERETTI, Elena , REYNOLDS, Joseph G. , ESPELIN, Christopher W.
IPC分类号： A61K39/395 , A61K9/127 , A61P35/00
CPC分类号： A61K39/39558 , A61J1/16 , A61K9/0019 , A61K9/127 , A61K9/1271 , A61K31/704 , A61K47/6871 , A61K47/6913 , A61K2039/507 , C07K16/2863 , C07K16/32 , C07K16/40 , C07K2317/76
摘要： Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
摘要翻译： 公开了治疗HER2阳性肿瘤患者的方法。 所述方法包括向患者施用治疗有效量的（i）负载蒽环类抗体的免疫脂质体与作为第一抗HER2抗体的靶向部分的组合，和（ii）包含第二抗HER2抗体的抗癌治疗剂 抗体。
-
4.发明授权
公开(公告)号：EP2544680B1
公开(公告)日：2015-01-14
申请号：EP11730112.7
申请日：2011-03-11
发明人： MOYO, Victor , GARCIA, Gabriela
IPC分类号： A61P35/00 , A61K31/337 , A61K31/517 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/28 , C07K16/30 , C07K16/32
CPC分类号： C07K16/32 , A61K31/337 , A61K31/517 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2863 , C07K16/3015 , C07K16/40 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
-
5.发明公开ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH PACLITAXEL FOR TREATMENT OF GYNECOLOGICAL CANCERS 审中-公开联合紫杉醇ERBB3抗体治疗妇科癌症的
公开(公告)号：EP2726100A2
公开(公告)日：2014-05-07
申请号：EP12803745.4
申请日：2012-06-13
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K31/337 , A61K39/39558 , A61K2039/545 , C07K16/32 , A61K2300/00
摘要： Provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-ErbB3 antibodies combined with paclitaxel.
-
公开(公告)号：EP2648753A2
公开(公告)日：2013-10-16
申请号：EP11847515.1
申请日：2011-12-12
IPC分类号： A61K39/395 , A61K47/48
CPC分类号： A61K47/48338 , A61K47/50 , A61K47/65 , A61K2039/505 , A61K2039/545 , C07K16/32 , C07K2317/31 , C07K2317/622
摘要： Disclosed are methods for the therapeutic administration of bispecific scFv conjugates as single doses at at least weekly intervals. In certain embodiments the conjugate is MM-111 and is administered at intervals of every two weeks or every three weeks. In other embodiments a single loading dose of MM-111 is administered to a human patient followed at at least weekly intervals by a least a single maintenance dose of MM- 111. The loading dose is larger than the maintenance dose.
-
7.发明公开METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN 有权VERFAHREN ZUR BEHANDLUNG VONBAUCHSPEICHELDRÜSENKREBSMITHILFE VON KOMBINATIONSTHERAPIEN MT LIPOSOMALEM IRINOTECAN
公开(公告)号：EP2861210A1
公开(公告)日：2015-04-22
申请号：EP13731230.2
申请日：2013-06-12
发明人： BAYEVER, Eliel , DHINDSA, Navreet , FITZGERALD, Jonathan, Basil , LAIVINS, Peter , MOYO, Victor , NIYIKIZA, Clet
IPC分类号： A61K9/00 , A61K31/4745 , A61K31/513 , A61K31/517 , A61P35/00
CPC分类号： A61K31/4745 , A61K9/0019 , A61K9/127 , A61K9/1271 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/573 , A61K45/06 , A61K2300/00
摘要： Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
摘要翻译： 提供了通过单独施用脂质体伊立替康（MM-398）或与另外的治疗剂组合来治疗患者胰腺癌的方法。 在一个实施方案中，脂质体伊立替康（MM-398）与5-氟尿嘧啶和甲酰四氢叶酸共同施用。
-
8.发明公开DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTI-CANCER THERAPEUTICS 审中-公开具有抗恶性肿瘤药剂量和给药方法特异性scFv结合物组合
公开(公告)号：EP2847226A2
公开(公告)日：2015-03-18
申请号：EP13787365.9
申请日：2013-05-13
发明人： FRYE, Sasha , McDONAGH, Charlotte , MOYO, Victor
IPC分类号： C07K16/30
CPC分类号： A61K39/39558 , A61K31/337 , A61K31/517 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K2317/31 , A61K2300/00
摘要： Provided are methods and compositions for clinical treatment of advanced HER2 positive solid tumors cancer using combination therapies comprising bispecific anti-ErbB2/anti-ErbB3 antibodies.
-
公开(公告)号：EP2686015A2
公开(公告)日：2014-01-22
申请号：EP12714108.3
申请日：2012-03-15
发明人： GARCIA, Gabriela , KUBASEK, William , LAHDENRANTA, Maria, Johanna , MACBEATH, Gavin , MCDONAGH, Charlotte , MOYO, Victor , ONSUM, Matthew, David , SEVECKA, Mark , WAINSZELBAUM, Marisa , ZHANG, Bo , SCHOEBERL, Birgit
IPC分类号： A61K39/395 , A61K31/00 , A61K33/00 , C07K16/32
CPC分类号： C07K16/32 , A61K31/337 , A61K31/513 , A61K31/517 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/55 , C07K16/2863 , C07K2317/31 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided.
-
10.发明公开USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS 有权ERBB3-抑制剂在三阴性乳腺癌治疗中的应用
公开(公告)号：EP2544680A2
公开(公告)日：2013-01-16
申请号：EP11730112.7
申请日：2011-03-11
发明人： MOYO, Victor , GARCIA, Gabriela
IPC分类号： A61K31/337
CPC分类号： C07K16/32 , A61K31/337 , A61K31/517 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2863 , C07K16/3015 , C07K16/40 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor,
e.g. , an anti- ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor,
e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.017 秒)
